1. Juraskova I, Butow P, Robertson R, et al. Post-treatment sexual adjustment following cervical and endometrial cancer: a qualitative insight. Psychooncology 2003;12:267–79.
2. Bodurka DC, Sun CC. Sexual function after gynecologic cancer. Obstet Gynecol Clin North Am 2006;33:621–30, ix.
3. Andersen BL, Woods XA, Copeland LJ. Sexual self-schema and sexual morbidity among gynecologic cancer survivors. J Consult Clin Psychol 1997;65:221.
4. Park ER, Norris RL, Bober SL. Sexual health communication during cancer care: barriers and recommendations. Cancer J 2009;15:74–7.
5. Stead ML, Brown JM, Fallowfield L, et al. Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. Br J Cancer 2003;88:666–71.
6. Stead ML, Fallowfield L, Brown JM, et al. Communication about sexual problems and sexual concerns in ovarian cancer: qualitative study. BMJ 2001;323:836–7.
7. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537–44.
8. American Psychiatric Association. Diagnostic and statistical manual of mental health disorders. 4th ed. 2000.
9. Elder JA, Braver Y. Female sexual dysfunction. In: Current clinical medicine. Elsevier; 2010:1222–6.
10. Ferrell BR, Dow KH, Leigh S, et al. Quality of life in long-term cancer survivors. Oncol Nurs Forum 1995;22:915–22.
11. Shamspour N, Assari S, Moghana Lankarani M. Relation between sexuality and health-related quality of life. In: Handbook of disease burdens and quality of life measures. New York: Springer 2010;3457–73.
12. Kim SI, Lee Y, Lim MC, et al. Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women. J Gynecol Oncol 2015;26:148–54.
13. Levin AO, Carpenter KM, Fowler JM, et al. Sexual morbidity associated with poorer psychological adjustment among gynecological cancer survivors. Int J Gynecol Cancer 2010;20:461–70.
14. Lutgendorf SK, Anderson B, Rothrock N, et al. Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. Cancer 2000;89:1402–11.
15. Tierney DK. Sexuality: a quality-of-life issue for cancer survivors. Semin Oncol Nurs 2008;24:71–9.
16. Brotto LA, Heiman JR, Goff B, et al. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. Arch Sex Behav 2008;37:317–29.
17. Hollingsworth M, Berman J. The role of androgens in female sexual dysfunction. Sex Reprod Menopause 2006;4:27–32.
18. Brand AH, Bull CA, Cakir B. Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix. Int J Gynecol Cancer 2006;16:288–93.
19. Lancaster L. Preventing vaginal stenosis after brachytherapy for gynaecological cancer: an overview of Australian practices. Eur J Oncol Nurs 2004;8:30–9.
20. Ponto JA, Barton D. Husbands’ perspective of living with wives’ ovarian cancer. Psychooncology 2008;17:1225–31.
21. Hartmann U, Philippsohn S, Heiser K, et al. Low sexual desire in midlife and older women: personality factors, psychosocial development, present sexuality. Menopause 2004;11:726–40.
22. Hawkins Y, Ussher J, Gilbert E, et al. Changes in sexuality and intimacy after the diagnosis and treatment of cancer: the experience of partners in a sexual relationship with a person with cancer. Cancer Nurs 2009;32:271–80.
23. Gilbert E, Ussher JM, Hawkins Y. Accounts of disruptions to sexuality following cancer: the perspective of informal carers who are partners of a person with cancer. Health 2009;13:523–41.
24. Hodgkinson K, Butow P, Hunt GE, et al. Life after cancer: couples’ and partners’ psychological adjustment and supportive care needs. Support Care Cancer 2007;15:405–15.
25. Lopez V, Copp G, Molassiotis A. Male caregivers of patients with breast and gynecologic cancer: experiences from caring for their spouses and partners. Cancer Nurs 2012;35:402–10.
26. American Cancer Society. Facts and figures 2015.
27. Michaelson-Cohen R, Beller U. Managing menopausal symptoms after gynecological cancer. Curr Opin Oncol 2009;21:407–11.
28. Biglia N Gadducci A, Ponzone R. Hormone replacement therapy in cancer survivors. Maturitas 2004;48:333–46.
29. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987;26:169–77.
30. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors. Cancer 1999;86:1013–8.
31. Creasman WT. Hormone replacement therapy after cancers. Curr Opin Oncol 2005;17:493–9.
32. Bebar S, Ursic-Vrscaj M. Hormone replacement therapy after epithelial ovarian cancer treatment. Eur J Gynaecol Oncol 2000;21:192–6.
33. Wen Y, Huang H, Huang H, et al. The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric 2013;16:673–81.
34. Creasman WT, Henderson D, Hinshaw W, et al. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326–30.
35. Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:587–92.
36. Lee K-B, Lee J-M, Lee J-K, et al. Endometrial cancer patients and tibolone: A matched case–control study. Maturitas 2006;55:264–9.
37. Kenemans P, Bundred NJ, Foidart J-M, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135–46.
38. Al-Baghdadi O, Ewies AAA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009;12:91–105.
39. Galuppi A, Perrone AM, La Macchia M, et al. Local α-tocopherol for acute and short-term vaginal toxicity prevention in patients treated with radiotherapy for gynecologic tumors. Int J Gynecol Cancer 2011;21:1708–11.
40. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4–20.
41. Bø K. Pelvic floor muscle training in treatment of female stress urinary incontinence, pelvic organ prolapse and sexual dysfunction. World J Urol 2012;30:437–43.
42. Dumoulin C, Hay-Smith EJC, Mac Habée-Séguin G. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2014;5:CD005654.
43. Rosenbaum TY. Pelvic floor involvement in male and female sexual dysfunction and the role of pelvic floor rehabilitation in treatment: A literature review. J Sex Med 2007;4:4–13.
44. Yang EJ, Lim J-Y, Rah UW, et al. Effect of a pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: a randomized controlled trial. Gynecol Oncol 2012;125:705–11.
45. Johnson N, Miles TP, Cornes P. Dilating the vagina to prevent damage from radiotherapy: systematic review of the literature. BJOG 2010;117:522–31.
46. Friedman LC, Abdallah R, Schluchter M, et al. Adherence to vaginal dilation following high dose rate brachytherapy for endometrial cancer. Int J Radiat Oncol Biol Phys 2011;80:751–7.
47. Cullen K, Fergus K, DasGupta T, et al. From “sex toy” to intrusive omposition: a qualitative examination of women’s experiences with vaginal dilator use following treatment for gynecological cancer. J Sex Med 2012;9:1162–73.
48. Robinson JW, Faris PD, Scott CB. Psychoeducational group increases vaginal dilation for younger women and reduces sexual fears for women of all ages with gynecological carcinoma treated with radiotherapy. Int J Radial Oncol Biol Phys 1999;44:497–506.
49. Stavraka C, Ford A, Ghaem-Maghami S, et al. A study of symptoms described by ovarian cancer survivors. Gynecol Oncol 2012;125:59–64.
50. Moonsammy SH, Guglietti CL, Mina DS, et al. A pilot study of an exercise & cognitive behavioral therapy intervention for epithelial ovarian cancer patients. J Ovarian Res 2013;6:21.
51. Goerling U, Jaeger C, Walz A, et al. The efficacy of short-term psycho-oncological interventions for women with gynaecological cancer: a randomized study. Oncology 2014;87:114–24.
52. Brotto LA, Erskine Y, Carey M, et al. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012;125:320–5.
53. Cleary V, McCarthy G, Hegarty J. Development of an educational intervention focused on sexuality for women with gynecological cancer. J Psychosoc Oncol 2012;30:535–55.
54. Miller BE, Pittman B, Strong C. Gynecologic cancer patients’ psychosocial needs and their views on the physician›s role in meeting those needs. Int J Gynecol Cancer 2003;13:111–9.
55. Fang P, Tan K, Grover S, et al. Psychosocial encounters correlates with higher patient-reported functional quality of life in gynecological cancer patients receiving radiotherapy. Radiat Oncol 2015;10:34.
56. Hordern A, Grainger M, Hegarty S, et al. Discussing sexuality in the clinical setting: The impact of a brief training program for oncology health professionals to enhance communication about sexuality. Asia Pac J Clin Oncol 2009;5:270–7.
57. Simonelli LE, Pasipanodya E. Health disparities in unmet support needs of women with gynecologic cancer: an exploratory study. J Psychosoc Oncol 2014;32:727–34.
58. Barbera L, Fitch M, Adams L, et al. Improving care for women after gynecological cancer: the development of a sexuality clinic. Menopause 2011;18:1327–33.
59. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578–83.
60. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–63.
61. Wu C-S, Lu M-L, Liao Y-T, et al. Ovarian cancer and antidepressants. Psychooncology 2015;24:579–84.
62. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29:259–66.
63. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267–74.
64. Reed SD, Guthrie KA, Joffe H, et al. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2012;119:527–38.
65. Pérez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004;2:50–6.
66. Pérez DG, Loprinzi CL, Sloan J, et al. Pilot evaluation of bupropion for the treatment of hot flashes. J Palliat Med 2006;9:631–7.
67. Agarwal N, Singh S, Kriplani A, et al. Evaluation of gabapentin in management of hot flushes in postmenopausal women. Post Reprod Health 2014;20:36–8.
68. Guttuso T Jr, Kurlan R, McDermott MP, et al. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337–45.
69. Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011;29:3862–8.
70. Loibl S, Schwedler K, von Minckwitz G, et al. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. Ann Oncol 2007;18:689–93.
71. Aerts L, Enzlin P, Verhaeghe J, et al. Long-term sexual functioning in women after surgical treatment of cervical cancer stages IA to IB: a prospective controlled study. Int J Gynecol Cancer 2014;24:1527–34.
72. Bloom JR, Petersen DM, Kang SH. Multi-dimensional quality of life among long-term (5+ years) adult cancer survivors. Psychooncology 2007;16:691–706.
73. Pfaendler KS, Wenzel L, Mechanic MB, et al. Cervical cancer survivorship: long-term quality of life and social support. Clin Ther 2015;37:39–48.
74. Becker M, Malafy T, Bossart M, et al. Quality of life and sexual functioning in endometrial cancer survivors. Gynecol Oncol 2011;121:169–73.
75. Bifulco G, De Rosa N, Tornesello ML, et al. Quality of life, lifestyle behavior and employment experience: a comparison between young and midlife survivors of gynecology early stage cancers. Gynecol Oncol 2012;124:444–51.
76. Vaz AF, Pinto-Neto AM, Conde DM, et al. Quality of life and menopausal and sexual symptoms in gynecologic cancer survivors: a cohort study. Menopause 2011;18:662–9.
77. American Cancer Society. Sexuality for the woman with cancer. 2013. Available at www.cancer.org/treatment/treatmentsandsideeffects/physicalsideeffects/sexualsideeffectsinwomen/sexualityforthewoman/index.
